Insight Molecular Diagnostics Inc (IMDX)

Currency in USD
1.660
+0.070(+4.40%)
Closed·
1.730+0.070(+4.22%)
·
IMDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.5951.800
52 wk Range
1.5007.510
Key Statistics
Prev. Close
1.59
Open
1.64
Day's Range
1.595-1.8
52 wk Range
1.5-7.51
Volume
168.4K
Average Vol. (3m)
241.8K
1-Year Change
-72.3333%
Book Value / Share
-0.74
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMDX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.250
Upside
+336.75%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.250
(+336.75% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Hold---MaintainNov 18, 2026
Lucid Capital Markets
Buy8.00+381.93%-New CoverageAug 24, 2026
BTIG
Hold---MaintainMay 15, 2026
BTIG
Hold---MaintainApr 01, 2026
Needham
Buy9.00+442.17%-MaintainMar 27, 2026

Insight Molecular Diagnostics Inc Earnings Call Summary for Q3/2026

  • Insight Molecular posted Q3 revenue of $560K (160% above forecast) and adjusted loss of $0.10/share (58% better than expected); shares fell 23% nonetheless.
  • Company expects FDA submission by Jan. 21, 2027, with potential authorization by mid-May 2027; plans to target 67 kidney transplant centers in MolDX jurisdiction.
  • R&D expenses declined to $3.8M from $5.8M peak in Q4 2025; management says cash burn bottomed in Q2 and improved in Q3 as company nears commercialization.
  • Developing urine test for rejection detection and heart transplant assay for 2027; plans European IVDR filing by end of 2026 with mid-2027 clearance expected.
  • Stock weakness reflects financing concerns from announced capital raise and execution risks; InvestingPro rates financial health as 'WEAK' with negative $31M cash flow.
Last Updated: 11/16/2026, 05:36 PM
Read Full Transcript

Earnings

Latest Release
Nov 16, 2026
EPS / Forecast
-0.10 / -0.24
Revenue / Forecast
560K / 215.12K
EPS Revisions
Last 90 days

IMDX Income Statement

Compare IMDX to Peers and Sector

Metrics to compare
IMDX
Peers
Sector
Relationship
P/E Ratio
−1.3x−43.1x−0.2x
PEG Ratio
−0.031.680.00
Price / Book
−2.2x−35.2x2.6x
Price / LTM Sales
27.6x9.2x2.7x
Upside (Analyst Target)
336.7%41.1%69.6%
Fair Value Upside
Unlock−15.1%11.7%Unlock

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.13M3.45%1.79M
Other Institutional Investors
36.42M96.55%57.92M
Public Companies & Retail Investors
0.000.00%0.00
Total
37.55M100.00%59.71M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Broadwood Capital, Inc.38.76%12,684,88420,169
Broadwood Partners LP38.76%12,684,88420,169

People Also Watch

0.968
KDK
-8.64%
44.91
CRWV
-6.11%
96.92
NBIS
-9.39%
1.340
RBBN
-2.90%
7.930
MBRX
+17.48%

FAQ

What Is the Insight Molecular Diagnostics (IMDX) Stock Price Today?

The Insight Molecular Diagnostics stock price today is 1.660 USD.

What Stock Exchange Does Insight Molecular Diagnostics Trade On?

Insight Molecular Diagnostics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Insight Molecular Diagnostics?

The stock symbol for Insight Molecular Diagnostics is "IMDX."

What Is the Insight Molecular Diagnostics Market Cap?

As of today, Insight Molecular Diagnostics market cap is 52.030M USD.

What Is Insight Molecular Diagnostics's Earnings Per Share (TTM)?

The Insight Molecular Diagnostics EPS (TTM) is -1.20.

When Is the Next Insight Molecular Diagnostics Earnings Date?

Insight Molecular Diagnostics will release its next earnings report on Apr 01, 2027.

From a Technical Analysis Perspective, Is IMDX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Insight Molecular Diagnostics Stock Split?

Insight Molecular Diagnostics has split 1 times.

How Many Employees Does Insight Molecular Diagnostics Have?

Insight Molecular Diagnostics has 57 employees.

What is the current trading status of Insight Molecular Diagnostics (IMDX)?

As of Nov 19, 2026, Insight Molecular Diagnostics (IMDX) is trading at a price of 1.660 USD, with a previous close of 1.590 USD. The stock has fluctuated within a day range of 1.595 USD to 1.800 USD, while its 52-week range spans from 1.500 USD to 7.510 USD.

What Is Insight Molecular Diagnostics (IMDX) Price Target According to Analysts?

The average 12-month price target for Insight Molecular Diagnostics is 7.250 USD, with a high estimate of 12 USD and a low estimate of 4 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +336.75% Upside potential.

What Is the IMDX Premarket Price?

IMDX's last pre-market stock price is 1.520 USD. The pre-market share volume is 1,230.000, and the stock has decreased by -0.070, or -4.400%.

What Is the IMDX After Hours Price?

IMDX's last after hours stock price is 1.730 USD, the stock has decreased by 0.070, or 4.220%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.